LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Kodu・Aktsiate loetelu・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Suletud

SektorTervishoid

23.65 -0.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

23.4

Max

23.98

Põhinäitajad
By Trading Economics
Sissetulek	-7.3M -68M
Müük	23M 68M
Kasumimarginaal	-99.318
Töötajad	298
EBITDA	42M -15M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+77.28% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. mai 2026

Turustatistika
By TradingEconomics
Turukapital	391M 2.1B
Eelmine avamishind	24.11
Eelmine sulgemishind	23.65

Uudiste sentiment

By Acuity

50%

171 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

9.91 / 14.15 Toetus ja vastupanu

Syndax Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. märts 2026, 22:51 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18. märts 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18. märts 2026, 20:31 UTC

Tulu

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18. märts 2026, 23:49 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18. märts 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18. märts 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18. märts 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18. märts 2026, 22:36 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18. märts 2026, 22:24 UTC

Tulu

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18. märts 2026, 21:58 UTC

Tulu

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18. märts 2026, 21:55 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

18. märts 2026, 21:55 UTC

Market Talk

Tulu

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18. märts 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18. märts 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18. märts 2026, 21:00 UTC

Uudisväärsed sündmused

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18. märts 2026, 20:58 UTC

Tulu

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18. märts 2026, 20:41 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:29 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:25 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:17 UTC

Tulu

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18. märts 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18. märts 2026, 20:09 UTC

Tulu

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18. märts 2026, 20:07 UTC

Tulu

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18. märts 2026, 20:06 UTC

Tulu

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Gross Margin About 81% >MU

18. märts 2026, 20:03 UTC

Tulu

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Võrdlus sarnastega

Hinnamuutus

Syndax Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

77.28% tõus

12 kuu keskmine prognoos

Keskmine 42.14 USD 77.28%

Kõrge 57 USD

Madal 28 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Syndax Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Syndax Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

9.91 / 14.15Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

171 / 351 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.